title: [Epidemiological profile of ovarian cancer].
abstract: BACKGROUND
  In Mexico, ovarian cancer represents 5.3% of cancer diagnoses in all age groups and 21% of gynecologic cancers. The states with the highest incidence of this disease Nuevo León, Mexico State and Federal District.
  
  
  OBJECTIVE
  To determine the epidemiological profile of ovarian cancer.
  
  
  METHODS
  A retrospective cross-sectional study that included all patients with complete records, diagnosed with ovarian cancer treated at the Oncology department UMAE Monterrey No. 23, January 2009 to 31 December 2009.
  
  
  RESULTS
  We identified 40 patients with ovarian cancer. The average age of menarche was 12.7 years, 40% were of reproductive age, 25% were nulliparous, 15% had a pregnancy and 37.5% had two pregnancies. Of the total patients, 17% had a history of breast cancer, 40% used a contraceptive method, 37% used oral contraceptives. The tumor marker CA 125 was found in 40% of patients, 63.1% had ultrasound markers for cancer. The most frequent clinical stage 1A in which they found 32% of cases. Papillary serous adenocarcinoma was diagnosed in 25% of patients, endometroid adenocarcinoma and mucinous tumor of low malignant potential was diagnosed borderline at 20%, poorly differentiated adenocarcinoma in 18% tumor granulosa cells in 7% and papillary adenocarcinoma ring cell adenocarcinoma in 5%. In total, 43% of patients received chemotherapy.
  
  
  CONCLUSIONS
  The majority of cases tenia50 years or more. The background was the most frequent hereditary breast cancer. There were no deaths during the study.
authors.affiliation: Hospital lgnacio Morones Prieto, Unidad Médica de Alta Especialidad número 23, Departamento de Oncología, Instituto Mexicano del Seguro Social.
authors.forename: Luz María
authors.initials: LM
authors.lastname: Rivas-Corchado
authors.forename: Manuel
authors.initials: M
authors.lastname: González-Geroniz
authors.forename: Ricardo Jorge
authors.initials: RJ
authors.lastname: Hernández-Herrera
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics / Q000601:surgery; D000328:Adult; D000367:Age Factors; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics; D018394:CA-125 Antigen / Q000097:blood; D003267:Contraception / Q000379:methods / Q000706:statistics & numerical data; D003430:Cross-Sectional Studies; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000453:epidemiology / Q000235:genetics; D006106:Granulosa Cell Tumor / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000601:surgery; D020249:Hormone Replacement Therapy / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics / Q000601:surgery; D010298:Parity; D011247:Pregnancy; D017584:Reproductive History; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen